- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Questions arise over GE bid
GE may not get all it wants from its bid to acquire Instrumentarium. The London-based Financial Times reports that GE may have to sell off some assets to obtain permission from the European Union for the takeover. Brussels is pushing hard for concessions
GE may not get all it wants from its bid to acquire Instrumentarium. The London-based Financial Times reports that GE may have to sell off some assets to obtain permission from the European Union for the takeover. Brussels is pushing hard for concessions as part of a probe into the effects of the proposed merger. The probe was launched by the EU in early April (SCAN 4/16/03). Regulators' concerns have been heightened by objections to the deal from GE rivals Siemens and Philips, according to the Times.
The sale of at least some of Instrumentarium's patient monitoring business might be the price GE will have to pay for the deal to go through, the Times reported. Other assets involving mobile x-ray and mammography equipment may also have to go. These demands could appear in a "statement of objections" to be sent to Instrumentarium and GE in the next few weeks. Joseph Hogan, president and CEO of GE Medical, predicted three months ago that no disposals would be needed in order to gain European approval. The final outcome is a long way from being decided, however, as the EU probe into the proposed deal is only in the early stages. The EU investigation is expected to continue into August.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.
